RxSight/$RXST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About RxSight
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Ticker
$RXST
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
498
ISIN
US78349D1072
Website
RxSight Metrics
BasicAdvanced
$344M
-
-$0.67
1.21
-
Price and volume
Market cap
$344M
Beta
1.21
52-week high
$58.23
52-week low
$6.32
Average daily volume
1.4M
Financial strength
Current ratio
12.683
Quick ratio
11.446
Long term debt to equity
3.934
Total debt to equity
4.311
Interest coverage (TTM)
-1,755.33%
Profitability
EBITDA (TTM)
-33.626
Gross margin (TTM)
71.87%
Net profit margin (TTM)
-17.90%
Operating margin (TTM)
-24.85%
Effective tax rate (TTM)
-0.22%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-9.29%
Return on equity (TTM)
-11.98%
Valuation
Price to revenue (TTM)
2.269
Price to book
1.23
Price to tangible book (TTM)
1.23
Price to free cash flow (TTM)
-16.405
Free cash flow yield (TTM)
-6.10%
Free cash flow per share (TTM)
-51.57%
Growth
Revenue change (TTM)
46.70%
Earnings per share change (TTM)
-46.38%
3-year revenue growth (CAGR)
74.21%
3-year earnings per share growth (CAGR)
-39.77%
What the Analysts think about RxSight
Analyst ratings (Buy, Hold, Sell) for RxSight stock.
Bulls say / Bears say
RxSight's Light Adjustable Lens (LAL) technology offers a unique post-cataract surgery solution, allowing for customized vision adjustments, which could drive increased adoption among ophthalmologists and patients. (seekingalpha.com)
The company reported a robust revenue growth of 28.40%, indicating strong demand for its innovative products and potential for continued market expansion. (directorstalkinterviews.com)
Analysts have set an average target price of $21.18 for RxSight, suggesting a potential upside of approximately 52.72% from the current price, reflecting confidence in the company's growth prospects. (directorstalkinterviews.com)
RxSight reported a significant decline in Light Delivery Device (LDD) sales, down 49% from the previous year and 45% from the previous quarter, indicating potential challenges in product adoption. (gurufocus.com)
The company revised its full-year 2025 revenue guidance downwards, now expecting a decrease of 14% to 7% compared to 2024, reflecting potential headwinds in achieving projected growth. (gurufocus.com)
RxSight faces intensified competition from new intraocular lens products by major players like Johnson & Johnson and Rayner, which could impact its market share and growth trajectory. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
RxSight Financial Performance
Revenues and expenses
RxSight Earnings Performance
Company profitability
RxSight News
AllArticlesVideos
Johnson Fistel Begins Investigation on Behalf of RxSight, Inc. (RXST) Shareholders
GlobeNewsWire·53 minutes ago
RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Business Wire·2 hours ago
Securities Fraud Investigation Into RxSight, Inc. (RXST) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Business Wire·20 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for RxSight stock?
RxSight (RXST) has a market cap of $344M as of July 11, 2025.
What is the P/E ratio for RxSight stock?
The price to earnings (P/E) ratio for RxSight (RXST) stock is 0 as of July 11, 2025.
Does RxSight stock pay dividends?
No, RxSight (RXST) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next RxSight dividend payment date?
RxSight (RXST) stock does not pay dividends to its shareholders.
What is the beta indicator for RxSight?
RxSight (RXST) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.